iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer

Sponsor
Royal Marsden NHS Foundation Trust
Study ID
NCT03867799
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single-arm, single centre open-label, phase II interventional clinical trial of combination immunotherapy with Nivolumab and Relatlimab in mCRC.

Key Dates

Start date
Mar 27, 2019
Status verified
Jun 2024
Primary completion
Oct 21, 2022
Completion
Sep 30, 2024

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab and Relatlimab
    Nivolumab 480mg and Relatlimab 160mg will be administered intravenously every 4 weeks

Primary Outcome Measure

Disease Control Rate (DCR) [ Time Frame: 6 months from treatment initiation ]

Related Studies